ArticleEmerging infectious diseases2008
Occurrence and clinical relevance of Mycobacterium chimaera sp. nov., Germany.
Article in Emerging infectious diseases, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 80 citations in OpenAlex.
- The Spread ofPathogens (Basel, Switzerland) · 2024Review
- The State-of-the-Art ofHealthcare (Basel, Switzerland) · 2024Review
- Characterisation and antimicrobial susceptibility pattern of non-tuberculous mycobacteria.Southern African journal of infectious diseases · 2024Article
- Differences in Drug-Susceptibility Patterns betweenAntibiotics (Basel, Switzerland) · 2022Article
- Pharmacologic Management ofOpen forum infectious diseases · 2022Review
- Article
- Searching for new therapeutic options for the uncommon pathogen Mycobacterium chimaera: an open drug discovery approach.The Lancet. Microbe · 2022Article
- SnackNTM: An Open-Source Software for Sanger Sequencing-based Identification of Nontuberculous Mycobacterial Species.Annals of laboratory medicine · 2022Article
- Article
- Risk Management in the New Frontier of Professional Liability for Nosocomial Infection: Review of the Literature on Mycobacterium Chimaera.International journal of environmental research and public health · 2020Review
- General Overview of Nontuberculous Mycobacteria Opportunistic Pathogens:Journal of clinical medicine · 2020Review
- DisseminatedFrontiers in medicine · 2020Article
- Article
- Treatment ofTuberculosis and respiratory diseases · 2019Review
- Evaluation of the VITEK MS knowledge base version 3.0 for the identification of clinically relevant Mycobacterium species.Emerging microbes & infections · 2018Article
- Skin and Soft Tissue Infections Due to Nontuberculous Mycobacteria.Current infectious disease reports · 2018Review
- Evaluation of a Novel MALDI Biotyper Algorithm to DistinguishFrontiers in microbiology · 2018Article
- Complete Genome Sequence ofGenome announcements · 2017Article
- Target-Specific Assay for Rapid and Quantitative Detection of Mycobacterium chimaera DNA.Journal of clinical microbiology · 2017Article
- Evaluation of GenoType NTM-DR Assay for Identification of Mycobacterium chimaera.Journal of clinical microbiology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Retrospective molecular genetic analysis of 166 Mycobacterium intracellulare isolates showed that 143 (86%) strains could be assigned to Mycobacterium chimaera sp. nov. Of 97 patients from whom M. chimaera sp. nov. was isolated, only 3.3% exhibited mycobacterial lung disease, whereas all M. intracellulare isolates caused severe pulmonary infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.